Tata Memorial Centre asserts that its Rs 100 per tablet medication has the potential to prevent cancer recurrence. The tablet, developed by the institute, aims to not only prevent cancer from returning but also reduce treatment side effects by half. Currently awaiting approval from FSSAI, once sanctioned, the tablet is anticipated to be available in the market by June.
Trending
- Amazon to Invest $50 Billion in OpenAI, AWS Becomes Exclusive Cloud Partner in Landmark AI Deal
- CBI Moves Delhi HC Against Discharge of Kejriwal, Sisodia in Excise Policy Case
- SBI Life-Backed Paisalo Digital Raises ₹30 Crore via Commercial Papers; NBFC Stock Under ₹50 in Focus
- Omnitech Engineering IPO Subscribed 1.20x on Final Day; QIB Demand Lifts ₹583 Crore Issue
- Acetech E-Commerce IPO Subscribed 0.26x on Day 1
- FIIs Dump ₹7,536 Crore in Single Day; DIIs Record Highest Buying Since October as Sensex Tanks 961 Points
- Electric Two-Wheeler Sales Cross 1 Lakh in Feb 2026; TVS Leads, Ola Trails
- Earthood Services Withdraws IPO Papers Filed with SEBI
- India to Cross $4 Trillion GDP by 2026-27; FY27 Growth Seen at 7–7.4%, Says CEA
- Temple Secures $54M: Deepinder Goyal’s Next Big Bet After Eternal
Ensuring Authenticity, Upholding Trust
